Skip to main content
Log in

Pseudoprogression oder Pseudorespons: Herausforderung an die Bildgebung des Glioblastoma multiforme

Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme

  • Themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

This methodological paper on magnetic resonance tomography imaging recalls the assessment criteria on therapy response of Glioblastoma multiforme as defined by David Macdonald in 1990 that have remained State of the Art since their first publication. It defines the terms "pseudoprogression", "radiation induced necrosis" and "pseudoresponse". These phenomena are seen increasingly since the introduction of radiochemotherapy with Temozolomide as treatment standard in glioblastoma and since the use of antiangiogenetic therapy in malignant gliomas. Therefore, the assessment criteria have been recently updated with the newly proposed "RANO criteria (Response assessment in Neuro-Oncology)". Furthermore, the potential of additional information to conventional MR by MR perfusion, MR diffusion and MR spectroscopy is briefly discussed.

Zusammenfassung

Ausgehend von der Beurteilung des Therapieerfolgs bei Glioblastomen durch bildgebende Untersuchungen nach den Kriterien, die David Macdonald 1990 vorgeschlagen hatte und die seither unangefochten Standardinstrumente blieben, werden in diesem Beitrag die Begriffe "Pseudoprogression", "Radionekrose" und "Pseudorespons" definiert und anhand von Beispielen erklärt. Diese Phänomene werden im Zuge der Verbreitung der kombinierten Radiochemotherapie und der Einführung anti-angiogenetisch wirksamer Substanzen in die Therapie maligner Gliome häufiger beobachtet. Dies hat ein Update der Beurteilungskriterien maligner Gliome, den "RANO-Kriterien", notwendig gemacht. Außerdem werden mögliche Zusatzinformationen zur konventionellen MR-Untersuchung, die aus MR-Perfusion, MR-Diffusion und MR-Spektroskopie bei malignen Gliomen gewonnen werden kurz erläutert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Literatur

  • Central Brain Tumor Registry of the United States: Statistical report: Primary brain tumors in the United States, 2000–2004. http://www.cbtrus.org/reports/2007-2008/2007report.pdf

  • Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987–996, 2005

    Article  CAS  PubMed  Google Scholar 

  • Macdonald D, Cascino T, Schold SJ, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8: 1277–1280, 1990

    CAS  PubMed  Google Scholar 

  • van den Bent MJ, Vogelbaum MA, Wen PY, et al. End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol, 27: 2905–2908, 2009

    Article  PubMed  Google Scholar 

  • Macdonald DR. Neuro-oncology, SP-9, 2009

  • Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol, 9: 453–461, 2008

    Article  PubMed  Google Scholar 

  • Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer, 113: 405–410, 2008

    Article  CAS  PubMed  Google Scholar 

  • Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol, 82: 81–83, 2007

    Article  PubMed  Google Scholar 

  • Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol, 94: 97–101, 2009

    Article  CAS  PubMed  Google Scholar 

  • Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol, 26: 2192–2197, 2008

    Article  PubMed  Google Scholar 

  • Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol, 22: 633–638, 2009

    Article  PubMed  Google Scholar 

  • Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy – and chemotherapy-induced necrosis oft he brain after treatment. Radiology, 217: 377–384, 2000

    CAS  PubMed  Google Scholar 

  • Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys, 65: 499–508, 2006

    Article  PubMed  Google Scholar 

  • Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 13: 1253–1259, 2007

    Article  CAS  PubMed  Google Scholar 

  • Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 27(28): 4733–4740, 2009

    Article  CAS  PubMed  Google Scholar 

  • Cloughesy T, Vredenburgh JJ, Day B, et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. ASCO, Abstract No: 2008, 2010

  • Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology, 70: 779–787, 2008

    Article  CAS  PubMed  Google Scholar 

  • Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol, 91: 329–336, 2009

    Article  CAS  PubMed  Google Scholar 

  • Verhoeff JJC, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 16: 444, 2009

    Article  Google Scholar 

  • Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Cin Oncol, 28: 1963–1972, 2010

    Article  Google Scholar 

  • Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol, 30: 552–558, 2009

    Article  CAS  PubMed  Google Scholar 

  • Barajas RF, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology, 253: 486–496, 2009

    Article  PubMed  Google Scholar 

  • Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-Temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology, 256: 575–584, 2010

    Article  PubMed  Google Scholar 

  • Tsien C, Galban CJ, Chenevert TL, et al. Parametric Response Map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol, 28: 2293–2299, 2010

    Article  CAS  PubMed  Google Scholar 

  • Gerstner ER, Sorensen AG, Jain RK, et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol, 21: 728–735, 2008

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Franz Payer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Payer, F. Pseudoprogression oder Pseudorespons: Herausforderung an die Bildgebung des Glioblastoma multiforme. Wien Med Wochenschr 161, 13–19 (2011). https://doi.org/10.1007/s10354-010-0860-8

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-010-0860-8

Keywords

Schlüsselwörter

Navigation